Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Author Verified
ACE Report #8516
Ace Report Cover Spine

CT-P13 comparable to infliximab at 54 weeks for ankylosing spondylitis

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study

Arthritis Res Ther. 2016 Jan 20;18(1):25

Contributing Authors: W Park DH Yoo J Jaworski J Brzezicki A Gnylorybov V Kadinov IG Sariego C Abud-Mendoza WJ Escalante SW Kang D Andersone F Blanco SS Hong SH Lee J Braun

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


250 ankylosing spondylitis patients were randomized to receive 5mg/kg of either CT-P13 or Infliximab through intravenous infusion for 54 weeks. The purpose of this study was to compare CT-P13, a biosimilar drug, to a known efficacious treatment of this pathology to determine its efficacy, immunogenicity, pharmacokinetics, and safety. The findings displayed similar results between groups for all pa...

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.